Subject: Medical Policy Updates

Dear Provider,

The following changes to the medical policy library become effective February 15, 2019:

Revised Policies

**MP 2.04.02 - Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers**

- An indication was added for “individuals with other high risk cancers such as cancers of the ovary, fallopian tubes, pancreas and prostate.”
- The first policy statement was updated to reflect changes to the National Comprehensive Cancer Network recommendation.
- The title of this policy changed to “Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers.”

**MP 2.04.33 - Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer**

- The SelectMDx, ExoDx Prostate (IntelliScore) and Apifiny tests were added as “investigational.”

**MP 2.04.36 - Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer**

- MammaPrint was added to the list of tests considered “medically necessary.”

**MP 2.04.111 - Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management**

- A new investigational indication was added for assays that detect androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with metastatic castration-resistant prostate cancer. This is used to predict resistance to androgen receptor signaling (ARS) inhibitors, such as abiraterone or enzalutamide.
- The policy statement is unchanged.

The changes listed above reflect the most current literature reviews on these indications. You can find additional information regarding these medical policies on our provider portal at [providers.bcidaho.com](http://providers.bcidaho.com).

Our medical policies are designed for informational purposes only. They are not an authorization, explanation of benefits or a contract. The delivery of benefits depends on the fulfillment of all terms and conditions of the coverage.

Medical technology is constantly changing, and we reserve the right to review and update our policies periodically. These policies may not apply to all lines of business, such as the Federal Employee Program, Medicare Advantage and certain self-insured groups.

Thank you for your cooperation and partnership.

Sincerely,

Judy Mouchawar, MD
*Medical Director, Medical Policy*
Blue Cross of Idaho